Hidroksiurea i nemelanomski karcinomi kože: prikaz tri bolesnika i pregled litrature

  • Tatjana Roš Clinical Center of Vojvodina, Clinic for Dermatovenereology, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Branislava Gajić Clinical Center of Vojvodina, Clinic for Dermatovenereology, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Zorica Gajinov Clinical Center of Vojvodina, Clinic for Dermatovenereology, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Milana Ivkov Simić Clinical Center of Vojvodina, Clinic for Dermatovenereology, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Slobodan Stojanović Clinical Center of Vojvodina, Clinic for Dermatovenereology, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Zoran Golušin Clinical Center of Vojvodina, Clinic for Dermatovenereology, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
DOI: https://doi.org/10.2298/VSP160218298R
Ključne reči: skin neoplasms||, ||koža, neoplazme, ultraviolet rays||, ||ultravioletni zraci, hydroxyurea||, ||hidroksiurea, treatment outcome||, ||lečenje, ishod,

Sažetak


Uvod. Hidroksiurea je citostatik koji se često koristi u terapiji mijeloproliferativnih oboljenja, anemije srpastih ćelija i težih oblika psorijaze. Neželjena dejstva na koži manifestuju se u oko trećine bolesnika lečenih hidroksiureom, među kojima je najozbiljnije neželjeno dejstvo sklonost pojavi nemelanomskih karcinoma kože. Prikaz bolesnika. U radu su prikazana tri bolesnika lečena hidroksiureom kod kojih je došlo do razvoja brojnih maligniteta kože u predelu glave, vrata i dorzuma šaka, redosledom prema nivou ukupne prisutne skvamozne displazije. Zaključak. Kumulativna doza hidroksiuree utiče na nastanak karcinoma kože u sadejstvu sa drugima faktorima rizika koji određuju kumulativnu izloženost ultraljubičastom zračenju (životno doba, fototip kože, obrazac izlaganja suncu), ali precizniji uticaj svakog od navedenih, kao i uticaj mogućih drugih kofaktora tek treba razjasniti. Ističemo važnost adekvatne prevencije i terapije karcinoma kože kod bolesnika lečenih hidroksiureom.

Reference

de Simone C, Guerriero C, Guidi B, Rotoli M, Venier A, Tartaglione R. Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. Eur J Dermatol 1998; 8(2): 114−5.

Rice L, Baker KR. Current management of the myeloprolifera-tive disorders: A case-based review. Arch Pathol Lab Med 2006; 130(8): 1151−6.

Kalajian AH, Cely SJ, Malone JC, Burruss JB, Callen JP. Hy-droxyurea-associated dermatomyositis-like eruption demon-strating abnormal epidermal p53 expression: A potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure. Arch Dermatol 2010; 146(3): 305−10.

Salmon-Ehr V, Leborgne G, Vilque JP, Potron G, Bernard P. Sec-ondary cutaneous effects of hydroxyurea: Prospective study of 26 patients from a dermatologic consultation. Rev Med In-terne 2000; 21(1): 30−4.

Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol 2004; 51(2): 293−300.

Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124(6): 869−71.

Vassallo C, Passamonti F, Merante S, Ardigo M, Nolli G, Mangi-acavalli S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Dermatol 2001; 26(1): 141−8.

Disdier P, Harle JR, Grob JJ, Weiller-Merli C, Magalon G, Weiller PJ. Rapid development of multiple squamous-cell carcinomas during chronic granulocytic leukemia. Dermatologica 1991; 183(1): 47−8.

Papi M, Didona B, DePita O, Abruzzese E, Stasi R, Papa G, et al. Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea. J Am Acad Dermatol 1993; 28(3): 485−6.

Angeli-Besson C, Koeppel MC, Jacquet P, Andrac L, Sayag J. Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia. Dermatology 1995; 191(4): 321−2.

Grange F, Couilliet D, Audhuy B, Krzisch S, Schlecht P, Guillaume JC. Multiple keratosis induced by hydroxyurea. Ann Dermatol Venereol 1995; 122(1−2): 16−8. (French)

Callot-Mellot C, Bodemer C, Chosidow O, Frances C, Azgui Z, Varet B, et al. Cutaneous carcinoma during long-term hydroxyurea therapy: a report of 5 cases. Arch Dermatol 1996; 132(11): 1395−7.

Daoud MS, Gibson LE, Pittelkow MR. Hydroxyureadermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1997; 36(2 Pt 1): 178−82.

Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: The pathogenesis and modeling of cu-taneous squamous cell carcinoma. J Clin Invest 2012; 122(2): 464−72.

Best PJ, Petitt RM. Multiple skin cancers associated with hy-droxyurea therapy. Mayo Clin Proc 1998; 73(10): 961−3.

Pamuk GE, Turgut B, Vural Ö, Demir M, Tek M, Altaner Ş. Met-astatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: Complication of hydroxyurea therapy. Clin Lab Haematol 2003; 25(5): 329−31.

Aste N, Fumo G, Biggio P. Multiple squamous epitheliomas dur-ing long-term treatment with hydroxyurea. J Eur Acad Derma-tol Venereol 2001; 15(1): 89−90.

Sakano K, Oikawa S, Hasegawa K, Kawanishi S. Hydroxyurea in-duces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn J Cancer Res 2001; 92(11): 1166−74.

Arif H, Rehmani N, Farhan M, Ahmad A, Hadi SM. Mobilization of copper ions by flavonoids in human peripheral lym-phocytes leads to oxidative DNA breakage: A structure activity study. Int J Mol Sci 2015; 16(11): 26754−9.

Radić J, Batinac T, Hadžisejdić I, Načinović-Duletić A, Valković T, Jonjić N. Concurrent basal cell and squamous cell carcinomas associated with hydroxyurea therapy. Acta Dermatovenerol Croat 2011; 19(3): 183−6.

Schleußinger TM, Dyall-Smith D, Field LM. Hydroxyurea-associated squamous dysplasia in a monozytic twin. J Am Acad Dermatol 2011; 65(3): 679−80.

Chaine B, Neonato MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 2001; 137: 467−70.

de Benedittis M, Petruzzi M, Giardina C, Muzio LL, Favia G, Serpico R. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin Exp Dermatol 2004; 29(6): 605−7.

Young HS, Khan ASA, Kendra JR, Coulson IH. The cutaneous side-effects of hydroxyurea. Clin Lab Haematol 2000; 22(4): 229−32.

Esteve E, Georgescu V, Heitzmann P, Martin L. Multiple skin and mouth squamous cell carcinomas related to long-term treat-ment with hydroxyurea. Ann Dermatol Venereol 2001; 128(8−9): 919−21. (French)

Wiechert A, Reinhard G, Tüting T, Uerlich M, Bieber T, Wenzel J. Multiple skin cancers in a patient treated with hydroxyurea. Hautarzt 2009; 60(8): 651−2, 654. (German)

Bouldouyre MA, Avril MF, Gaulier A, Sigal-Grinberg M. Associa-tion of cutaneous side-effects of hydroxyurea and neuroendo-crine carcinoma. Eur J Dermatol 2005; 15(4): 268−70.

Kraft S, Granter SR. Molecular pathology of skin neoplasms of the head and neck. Arch Pathol Lab Med 2014; 138(6): 759−87.

Saraceno R, Teoli M, Chimenti S. Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. Clin Ther 2008; 30(7): 1324−9.

Objavljeno
2017/11/28
Broj časopisa
Vol. 74 Br. 11 (2017)
Rubrika
Prikaz bolesnika